By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mast Therapeutics 

12390 El Camino Real, Suite 150

San Diego  California  92130  U.S.A.
Phone: 858-552-0866 Fax: 858-552-0876


Company News
Mast Therapeutics (MSTX) Reports Second Quarter 2016 Financial Results 8/9/2016 8:37:11 AM
Mast Therapeutics (MSTX) Awarded Small Business Innovation Research Grant From The NIH 8/8/2016 11:03:40 AM
Mast Therapeutics (MSTX) Announces Issuance Of Composition Of Matter Patent Covering Vepoloxamer 8/3/2016 6:51:02 AM
Mast Therapeutics (MSTX) To Present At 36th Annual Canaccord Genuity Growth Conference On August 10 8/2/2016 9:26:32 AM
Mast Therapeutics (MSTX) Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network 8/1/2016 7:02:24 AM
Mast Therapeutics (MSTX) Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer 6/9/2016 10:03:00 AM
Mast Therapeutics (MSTX) Release: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At European Society of Cardiology 3rd World Congress On Acute Heart Failure 5/23/2016 7:46:42 AM
Mast Therapeutics (MSTX) Release: Positive Interim Results From Second Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Presented At American Thoracic Society International Conference 5/16/2016 9:17:45 AM
Mast Therapeutics (MSTX) Reports First Quarter 2016 Financial Results And Recent Highlights 5/6/2016 6:59:48 AM
Mast Therapeutics (MSTX) Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network 4/13/2016 6:15:34 AM